Giant pituitary adenomas comprise about 6–10% of all pituitary tumors. They are mostly
clinically non-functioning adenomas and occur predominantly in males. The presenting …

The classification of neuroendocrine neoplasms (NENs) differs between organ systems and
currently causes considerable confusion. A uniform classification framework for NENs at any …

Objective: Pituitary adenomas are the third most common central nervous system tumors
and arise from the anterior pituitary within the pituitary fossa. Methods: Literature review and …

Objective To collect outcome data in a large cohort of patients with aggressive pituitary
tumours (APT)/carcinomas (PC) and specifically report effects of temozolomide (TMZ) …

Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded
to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable …

Purpose Pituitary tumors are the second most common intracranial tumors, however,
pituitary carcinoma is a rare clinical entity which represents only 0.1–0.2% of all pituitary …

Pituitary adenomas are unique in multiple ways. They are rarely malignant in terms of
metastases; yet, they may be aggressive. Their cancerous potential is defined in a classic …

Non-functioning pituitary carcinomas (NFPC) are defined as tumours of adenophyseal origin
with craniospinal or systemic dissemination, with the absence of a hormonal hypersecretion …

Introduction Non-functioning pituitary adenomas (NFPAs) are in general large tumors that
present with symptoms secondary to local pressure on adjacent structures. Transsphenoidal …

At least 50% of surgically resected non-functioning pituitary adenomas (NFPA) recur. Either
early or late adjuvant radiotherapy is highly efficacious in controlling recurrent NFPA but …